SEC Comment Letter for Salarius Pharmaceuticals, Inc. (DCOY) (CIK 0001615219) (DCOY) — Jan 14, 2020
Salarius Pharmaceuticals, Inc. (DCOY) (CIK 0001615219)
Date: Jan. 14, 2020 · CIK: 0001615219 · Accession: 0000000000-20-000340
AI Filing Summary & Sentiment
File numbers found in text: 333-235879
Letter
January 14, 2020 David J. Arthur President and Chief Executive Officer Salarius Pharmaceuticals, Inc. 2450 Holcombe Blvd. Suite J-608 Houston, TX 77021 Re:Salarius Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed January 10, 2020 File No. 333-235879 Dear Mr. Arthur: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact William Mastrianna, Attorney-Adviser, at (202) 551-3778 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
January 14, 2020
David J. Arthur
President and Chief Executive Officer
Salarius Pharmaceuticals, Inc.
2450 Holcombe Blvd.
Suite J-608
Houston, TX 77021
Re:Salarius Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed January 10, 2020
File No. 333-235879
Dear Mr. Arthur:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact William Mastrianna, Attorney-Adviser, at (202) 551-3778 with any
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences